Switching treatments in haemophilia: is there a risk of inhibitor development?

Patients with haemophilia A (and their physicians) may be reluctant to switch factor VIII (FVIII) concentrates, often due to concerns about increasing the risk of inhibitors; this reluctance to switch may contribute to patients missing the clinical benefits provided by the arrival of new factor VIII...

Descripción completa

Detalles Bibliográficos
Autores principales: Santagostino, Elena, Auerswald, Günter, Benson, Gary, Dolan, Gerry, Jiménez-Yuste, Victor, Lambert, Thierry, Ljung, Rolf, Morfini, Massimo, Remor, Eduardo, Zupančić Šalek, Silva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407931/
https://www.ncbi.nlm.nih.gov/pubmed/25135593
http://dx.doi.org/10.1111/ejh.12433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407931/
https://www.ncbi.nlm.nih.gov/pubmed/25135593
http://dx.doi.org/10.1111/ejh.12433

Ejemplares similares